| Autor: |
Atsuhiro Kishimoto, Maki Komiyama, Hiromichi Wada, Noriko Satoh-Asahara, Hajime Yamakage, Yoichi Ajiro, Hiroki Aoyama, Yasuhiro Katsuura, Atsushi Imaizumi, Tadashi Hashimoto, Yoichi Sunagawa, Tatsuya Morimoto, Masashi Kanai, Hideaki Kakeya, Koji Hasegawa |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Journal of Health, Population and Nutrition, Vol 43, Iss 1, Pp 1-8 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2072-1315 |
| DOI: |
10.1186/s41043-024-00584-6 |
| Popis: |
Abstract Introduction Even after the peak of the COVID-19 pandemic, the number of mild cases remains high, requiring continuous control. Curcumin, owing to its anti-inflammatory properties, can suppress vital proliferation and cytokine secretion in animal models. We developed a highly absorbable curcumin, curcuRouge® (cR), which is approximately 100 times more orally bioavailable than conventional curcumin. We evaluated the effect of cR on the inhibition of disease progression in asymptomatic or mildly symptomatic COVID-19 patients. Methods This study evaluated the effect of 7-day oral intake of cR (360 mg twice daily). Patients within 5 days of COVID-19 diagnosis were randomly assigned to a placebo or cR group in a double-blind manner. Results Primary endpoint events [body temperature (BT) ≥ 37.5 °C and saturation of percutaneous oxygen (SpO2) |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
